Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: Two systematic reviews

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 3, 2012, Pages 288-296

  Van Der Werf, Marieke J ^a,b   Langendam, M W ^b   Sandgren, A ^c   Manissero, D ^c  

^a KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

Latent TB; Multidrug resistance; Prevention

Indexed keywords

ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; CHEMOPROPHYLAXIS; CHILD; CLINICAL EVALUATION; CONTACT EXAMINATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEALTH CARE POLICY; HUMAN; INFANT; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CONTACT TRACING; HEALTH POLICY; HUMANS; POLICY MAKING; PRACTICE GUIDELINES AS TOPIC; RISK; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84857337449     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0437     Document Type: Review

References (85)

1. Smieja M J, Marchetti C A, Cook D J, et al. Isoniazid for preventing tuberculosis in non-HIV-infected persons. Cochrane Database Syst Rev 2000; CD001363.
2. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; CD000171.
3. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161 (4 Pt 2): S221-S247.
4. National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at NICE. NICE Clinical Guideline 117: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, UK: NICE, 2011.
5. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
6. Fraser A, Paul M, Attamna A, Leibovici L. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis 2006; 10: 19-23. (Pubitemid 43266272)
7. Fraser A, Paul M, Attamna A, et al. Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2006; CD005435.
8. Gandhi N R, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-1843.
9. A ministerial meeting of high M/XDR-TB burden countries. Beijing, China, 1-3 April 2009. http://www.who.int/tb-beijing meeting/en/index.html Accessed November 2011.
10. Cobelens F G, Heldal E, Kimerling M E, et al. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda. PLoS Med 2008; 5: e150.
11. Higgins J P T, Green S. Cochrane handbook for systematic reviews of interventions. Oxford, UK: The Cochrane Collaboration, 2011.
12. Shea B J, Grimshaw J M, Wells G A, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007; 7: 10.
13. Wells G A, Shea B J, O'Connell D, et al. The Newcastle Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm Accessed November 2011.
14. Guyatt G H, Oxman A D, Vist G E, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926. (Pubitemid 351632017)
15. Lardizabal A, Passannante M, Kojakali F, et al. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130: 1712-1717. (Pubitemid 46033423)
16. Becerra M C, Appleton S C, Franke M F, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011; 377: 147-152.
17. Chemardin J, Paty M C, Renard-Dubois S, et al. Contact tracing of passengers exposed to an extensively drug-resistant tuberculosis case during an air flight from Beirut to Paris, October 2006. Euro Surveill 2007; 12: E071206.
18. de Vries G, van Altena R, van Soolingen D, et al. [An outbreak of multiresistant tuberculosis from Eastern Europe in the Netherlands]. Ned Tijdschr Geneeskd 2005; 149: 1921-1924. [Dutch]
19. Huang Y-W, Shen G-H, Lee J-J, Yang W-T. Latent tuberculosis infection among close contacts of multidrug-resistant tuberculosis patients in central Taiwan. Int J Tuberc Lung Dis 2010; 14: 1430-1435.
20. Llacer R L, Gonong J R, Balanag V, et al. Contact tracing of MDR-TB patients at the lung center of the Philippines. Respirology (2010) 15 (Suppl. 2), 26-54. [Oral Presentation Abstract OS-06-06]
21. Miramontes R, Lambert L, Haddad M B, et al. Public health response to a multidrug-resistant tuberculosis outbreak among Guatemalans in Tennessee, 2007. South Med J 2010; 103: 882-886.
22. Palmero D, Ritacco V, Ruano S, et al. Multidrug-resistant tuberculosis outbreak among transvestite sex workers, Buenos Aires, Argentina. Int J Tuberc Lung Dis 2005; 9: 1168-1170. (Pubitemid 41433808)
23. Pankhania B, Thompson C, Nash K, et al. Tuberculosis contact tracing at a school in a low-incidence area. Thorax 2009; Conference: A127.
24. Pineiro Perez R, Mellado Pena M J, Mendez Echevarria A, et al. [Exposure to multiresistant tuberculosis: study and followup of nine children]. An Pediatr (Barc) 2008; 68: 490-495. [Spanish]
25. Younossian A B, Rochat T, Ketterer J P, et al. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005; 26: 462-464. (Pubitemid 41264210)
26. Cain K P, Nelson L J, Cegielski J P. Global policies and practices for managing persons exposed to multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2010; 14: 269-274.
27. Finnell S M, Christenson J C, Downs S M. Latent tuberculosis infection in children: a call for revised treatment guidelines. Pediatrics 2009; 123: 816-822.
28. Sneag D B, Schaaf H S, Cotton M F, et al. Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases. Pediatr Infect Dis J 2007; 26: 1142-1146. (Pubitemid 350190948)
29. Takashima T, Kawabe Y. Strategies against multidrug-resistant tuberculosis. Kekkaku 2004; 79: 669-687. [Japanese] (Pubitemid 40220341)
30. Feja K, McNelley E, Tran C S, et al. Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003. Pediatr Infect Dis J 2008; 27: 907-912.
31. Sasaki Y, Yamagishi F, Yagi T. [Current situation of contacts examination and chemoprophylaxis for persons exposed to multi-drug resistant tuberculosis in ordinance-designated cities in Japan]. Kekkaku 2005; 80: 637-642. [Japanese]
32. Tochon M, Bosdure E, Salles M, et al. Management of young children in contact with an adult with drug-resistant tuberculosis, France, 2004-2008. Int J Tuberc Lung Dis 2011; 15: 326-330.
33. Kritski A L, Marques M J, Rabahi M F, et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 153: 331-335.
34. Schaaf H S, Gie R P, Kennedy M, et al. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002; 109: 765-771. (Pubitemid 34493340)
35. Attamna A, Chemtob D, Attamna S, et al. Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort. Thorax 2009; 64: 271.
36. Balague M, Sanchez F, Fernandez S, et al. [Difficulties to enroll patients in non-remunerated clinical trials. Results from a clinical trial comparing two treatment options for latent tuberculosis infection]. Medicina Clinica 2004; 122: 115. [Spanish]
37. Brown J M, Boparai N, Brown M, et al. Chemoprophylaxis following an outbreak of isoniazid-resistant tuberculosis in a community school: compliance and tolerance in an adolescent population to a regime of rifampicin and ethambutol. Thorax 2009; 64 (Suppl VI): A123.
38. Cayla J, Sanchez F, Martinez L, et al. [Treatment of tuberculous infection (antituberculous chemoprophylaxis)]. Enfermedades Emergentes 2001; 3: 90-91. [Spanish]
39. De Pinho A M F, Santoro-Lopes G, Harrison L H, et al. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS 2001; 15: 2129-2135. (Pubitemid 33101820)
40. Gordin F. Short-term tuberculosis prophylaxis is effective in persons with HIV. Am Fam Physician 1998; 58: 948.
41. Higgins R M, Cahn A P, Porter D, et al. Mycobacterial infections after renal transplantation. Q J Med 1991; 78: 145-153.
42. LaMar J E II, Malakooti M A. Tuberculosis outbreak investigation of a US Navy amphibious ship crew and the marine expeditionary unit aboard, 1998. Mil Med 2003; 168: 523-527. (Pubitemid 36876944)
43. Macintyre C R, Ansari M Z, Carnie J, et al. No evidence for multiple-drug prophylaxis for tuberculosis compared with isoniazid alone in Southeast Asian refugees and migrants: completion and compliance are major determinants of effectiveness. Prev Med 2000; 30: 425-432. (Pubitemid 30252829)
44. Pang S C, Harrison R H, Brearley J, et al. Preventive therapy for tuberculosis in Western Australia. Int J Tuberc Lung Dis 1998; 2: 984-988. (Pubitemid 29005214)
45. Stein-Zamir C, Volovik I, Rishpon S, et al. Tuberculosis out-break among students in a boarding school. Eur Respir J 2006; 28: 986-991. (Pubitemid 46331969)
46. Torres G. A short two-drug regimen prevents active TB. GMHC Treat Issues 1998; 12: 12.
47. Centers for Disease Control and Prevention. Use of short-course tuberculosis preventive therapy regimens in HIV- seronegative persons. JAMA 1998; 280: 1736.
48. Amoudru C, Michot R, Azencott A, et al. [Prevention of tuberculosis in mining areas. The experience of the Nord and the Pas-de-Calais basin]. Acta Tuberculosea et Pneumologica Belgica 1975; 66: 128-137. [French]
49. Barton L L, Lepage P, De Rosa F G, et al. Treatment of latent tuberculosis infection (multiple letters). N Engl J Med 2003; 348: 1292-1294. (Pubitemid 36359311)
50. Geiter L J, O'Brien R J. From the Centers for Disease Control. Conference on new approaches for tuberculosis preventive therapy. J Infect Dis 1987; 156: 536-537.
51. Houston S, Long R, Hoeppner V, et al. Latent tuberculosis treatment (multiple letters). Can Med Assoc J 2002; 167: 452-454. (Pubitemid 35034608)
52. Johnston B L, Conly J M. Re-examining treatment of latent tuberculosis infection. Can J Infect Dis 2001; 12: 211-214. (Pubitemid 33020917)
53. Kirkland L R. Preventive therapy for multidrug-resistant tuberculosis. JAMA 1996; 276: 27-28.
54. Kritski A L. Tuberculosis preventive therapy for HIV-infected persons in less developed countries. Int J Tuberc Lung Dis 2000; 4 (Suppl 1): S76-S81. (Pubitemid 30121058)
55. Mitchison D A. Pyrazinamide in the chemoprophylaxis of tuberculosis. Am Rev Respir Dis 1990; 142: 1467.
56. Sane S V, Sane N S, Thakker S V, et al. Alternatives to INH chemoprophylaxis. Indian Pediatr 1995; 32: 935-937.
57. Sanklecha M U, Raghavan K, Mehta M N. Is INH alone enough for prophylaxis? Indian Pediatr 1995; 32: 105.
58. Shingadia D V, Baumer J H. Tuberculosis: diagnosis, management and prevention. Arch Dis Child Educ Pract Ed 2007; 92: ep27-ep29.
59. Singh N. Inching closer towards optimization of treatment for latent tuberculosis in liver transplant recipients. Transplantation 2007; 83: 1536-1537. (Pubitemid 46987901)
60. Yun J S, Lazarus A A, Gilbert R. Latent tuberculous infection. Disease-A-Month 2006; 52: 441-445. (Pubitemid 44853945)
61. Horn D L, Hewlett D Jr, Alfalla C, et al. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 1994; 330: 1241. (Pubitemid 24122002)
62. Ridzon R, Meador J, Maxwell R, et al. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 1997; 24: 1264-1265. (Pubitemid 27249040)
63. Lou H X, Shullo M A, McKaveney T P. Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. Pharmacotherapy 2002; 22: 701-704. (Pubitemid 34596478)
64. Bay M R, Gonzalez G, Pedrini M, et al. Evaluation of the therapeutic fulfilment in the treatment or profilaxis of tuberculosis. Latin American Journal of Pharmacy 2007; 26: 609-613. [Spanish] (Pubitemid 350189374)
65. Balague M, Sanchez F, Martin V, et al. Treatment of latent tuberculosis infection in HIV-positive persons. Enfermedades Emergentes 2002; 4: 209-212. [Spanish] (Pubitemid 36151992)
66. Cohn D L, Iseman M D. Treatment and prevention of multidrug-resistant tuberculosis. Res Microbiol 1993; 144: 150-158. (Pubitemid 23131008)
67. Conen D. Preventive chemotherapy for tuberculosis. Ars Medici 1985; 5: 299 (Table 5). [German]
68. Grosset J. Present and new drug regimens in chemotherapy and chemoprophylaxis of tuberculosis. Bull Int Union Tuberc Lung Dis 1990; 65 (2-3): 86-91. (Pubitemid 20385495)
69. Krebs A, Steinbrueck P, Renger F, et al. Perspective of tuberculosis control: role of preventive chemotherapy. Zeitschrift fur Erkrankungen der Atmungsorgane 1979; 153: 60-65. [German] (Pubitemid 10234805)
70. Laylavoix F. [Treatment in cases of tuberculin reaction conversion]. Bordeaux Medical 1980; 13: 329-330. [French]
71. Mlczoch F. [Preventive treatment of tuberculosis]. Wiener Medizinische Wochenschrift 1972; 122: 773-777. [German]
72. Moorman J P, Mandell G L. Prophylactic TB therapy: what options when INH toxicity develops? J Respir Dis 1998; 19: 933. (Pubitemid 28536090)
73. Nakhosteen J A. Prophylaxis and therapy of pulmonary tuberculosis. Atemwegs- und Lungenkrankheiten 1990; 16: 123-125. [German]
74. Press P. Prophylaxis, detection and treatment of pulmonary tuberculosis. Revue Medicale de la Suisse Romande 1982; 102: 249-255. [French] (Pubitemid 12084593)
75. Prignot J. [Tuberculosis: chemoprophylaxis and chemotherapy in 1992]. Louvain Medical 1992; 111: 9-16. [French]
76. Rey D R. Prophylaxis and treatment in associated infection of tuberculosis and HIV. Archivos de Bronconeumologia 1992; 28: 51-54. [Spanish]
77. Rodriguez F G, Bernal Bermudez J A, Egido A G. [Clinical management of latent tuberculosis]. Medicina Clinica 2001; 117: 111-114. [Spanish]
78. Rojas-Pache C, Cerruti F. [Mycobacterium tuberculosis infection and HIV. Approach, treatment and prophylaxis]. Medecine et Hygiene 1991; 49: 1569-1576. [French]
79. Schonian U, Schmidt M, Ringelmann R. [Preventive chemotherapy in tuberculosis]. Immunitat und Infektion 1986; 14: 208-209. [German]
80. Simon K. [Prophylactic and preventive measures in the fight against tuberculosis]. Beitrage zur Klinik und Erforschung der Tuberkulose und der Lungenkrankheiten 1968; 137: 151-158. [German]
81. Solsona P J, Jimenez Fuentes M A, Mila A C, et al. [Clinical management of latent tuberculosis]. Med Clin (Barc) 2002; 118: 636-638.
82. Van Deutekom H. Chemoprophylaxis and chemotherapy of tuberculosis in HIV infected patients. Bull Int Union Tuberc Lung Dis 1990; 65 (2-3): 84-85. (Pubitemid 20385493)
83. Zierski M, Mokrzycki M. [Antibiotics in preventive therapy of pulmonary tuberculosis]. Gruzlica 1951; 19: 459-478. [Polish]
84. Papastavros T, Dolovich L R, Holbrook A, et al. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 2002; 167: 131-136. (Pubitemid 34791519)
85. Teixeira L, Perkins M D, Johnson J L, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 321-328. (Pubitemid 32397582)